Antibody Production Market by Product, Type, Technology & by End-User- Analysis & Global Forecast to 2019

Over the years, the antibody production market has witnessed various technological advancements in order to produce antibodies that meet the needs of biotechnology and biopharmaceutical companies, diagnostic laboratories, and research institutes. These advancements have led to the development of hybridoma-free technologies such as recombinant technology and antibody phage-display technology. Due to the advantages of this technology, such as ease of use and versatility, the hybridoma-free technology is set to replace technologies that use hybridomas and animals in due course.

In 2014, the consumables segment accounted for the largest share of the global antibody production market, by product; the monoclonal antibody segment accounted for the largest share of the antibody production market, by type; the hybridoma technology segment accounted for the largest share of antibody production market, by technology; while the biotechnology and pharmaceutical companies segment accounted for the largest share of the antibody production market, by end user.

In 2014, North America accounted for the largest share of the global antibody production market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the antibody production market is expected to witness the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to increase revenues of antibody producers and the manufacturers of equipment and consumables involved in antibody production.

The global antibody production market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various strategies (agreements, partnerships, joint ventures, collaborations, geographical expansions, and acquisitions) to increase their market shares and to establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

‧ Market Penetration: Comprehensive information on the product portfolios offered by the top players in the antibody production market. The report analyzes the antibody production market, by product, type, technology, and end user

‧ Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the antibody production market

‧ Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various antibody production technologies across regions

‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the antibody production market

‧ Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the antibody production market

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1.1 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.1.1.1 Secondary research 21
2.1.2 KEY DATA FROM SECONDARY SOURCES 22
2.1.2.1 Primary research 23
2.1.2.2 Key industry insights 23
2.1.3 KEY DATA FROM PRIMARY SOURCES 25
2.1.4 KEY INSIGHTS FROM PRIMARY SOURCES 25
2.1.5 MARKET SIZE ESTIMATION METHODOLOGY 26
2.1.6 MARKET FORECAST METHODOLOGY 28
2.1.7 MARKET DATA VALIDATION AND TRIANGULATION 28
2.1.8 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CURRENT SCENARIO 31
3.3 FUTURE OUTLOOK 32
3.4 CONCLUSION 34
4 PREMIUM INSIGHTS 35
4.1 GLOBAL ANTIBODY PRODUCTION MARKET 35
4.2 ANTIBODY PRODUCTION MARKET, BY REGION AND END USER 36
4.3 GEOGRAPHIC SNAPSHOT OF THE ANTIBODY PRODUCTION MARKET 37
4.4 ANTIBODY PRODUCTION MARKET, BY TECHNOLOGY (2014 VS. 2019) 37
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.2 MARKET SEGMENTATION 39
5.3 MARKET DYNAMICS 40
5.3.1 DRIVERS 40
5.3.1.1 Increasing global demand for monoclonal antibodies (mAbs) 40
5.3.1.2 Rising R&D expenditure of pharmaceutical and biotechnology companies 41
5.3.2 CHALLENGES 42
5.3.2.1 High cost of primary antibodies 42
5.3.3 OPPORTUNITIES 42
5.3.3.1 Emerging markets of India and China 42
5.3.3.2 Rising demand for protein therapeutics 44
5.3.3.1 Increasing risk of infectious diseases 44
6 INDUSTRY TRENDS 45
6.1 SUPPLY CHAIN ANALYSIS 45
6.1.1 PROMINENT COMPANIES 45
6.1.2 SMALL AND MEDIUM ENTERPRISES 46
6.1.3 END USERS 46
6.1.4 KEY INFLUENCERS 46
6.1.4.1 Investors, Venture Capitalists, and Funding Bodies 46
6.1.4.2 Regulatory Bodies 46
6.1.4.3 Academic Researchers/Organizations 46
7 ANTIBODY PRODUCTION MARKET, BY PRODUCT 47
7.1 INTRODUCTION 48
7.2 EQUIPMENT 49
7.2.1 BIOREACTORS 49
7.2.2 CENTRIFUGES 50
7.2.3 ULTRAFILTRATION SYSTEMS 50
7.2.4 OTHER EQUIPMENT 50
7.3 CONSUMABLES 51
7.3.1 SERA 51
7.3.2 MEDIA 51
7.3.3 REAGENTS AND BUFFERS 52
7.3.4 CHROMATOGRAPHY RESINS AND COLUMNS 52
8 ANTIBODY PRODUCTION MARKET, BY TYPE 53
8.1 INTRODUCTION 54
8.2 MONOCLONAL ANTIBODIES 55
8.3 POLYCLONAL ANTIBODIES 57
?
9 GLOBAL ANTIBODY PRODUCTION MARKET, BY TECHNOLOGY 59
9.1 INTRODUCTION 60
9.1.1 HYBRIDOMA TECHNOLOGY 61
9.1.2 HYBRIDOMA-FREE TECHNOLOGY 61
10 ANTIBODY PRODUCTION MARKET, BY END USER 63
10.1 INTRODUCTION 64
10.1.1 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 65
10.1.2 DIAGNOSTIC LABORATORIES 66
10.1.3 RESEARCH INSTITUTES 66
11 ANTIBODY PRODUCTION MARKET, BY REGION 68
11.1 INTRODUCTION 69
11.2 PEST ANALYSIS 69
11.2.1 POLITICAL FACTORS 69
11.2.2 ECONOMIC FACTORS 69
11.2.3 SOCIAL FACTORS 70
11.2.4 TECHNOLOGICAL FACTORS 70
11.3 NORTH AMERICA 72
11.3.1 U.S. 75
11.3.1.1 Increase in monoclonal antibody (mAb) production 75
11.3.1.2 Increase in bio-based drug research 76
11.3.2 CANADA 77
11.3.2.1 Regulatory Approvals and Authorizations for Use of mAbs in Canada 77
11.4 EUROPE 80
11.4.1 GERMANY 83
11.4.1.1 Advances in the biotechnological & research sectors 83
11.4.2 U.K. 84
11.4.2.1 Increase in R&D investments 84
11.4.3 FRANCE 86
11.4.3.1 Large number of research institutes in France 86
11.4.4 REST OF EUROPE (ROE) 88
11.4.4.1 Investments and Funding for Life Sciences to Bolster the Antibody Production Market 88
11.5 ASIA 90
11.5.1 JAPAN 93
11.5.1.1 Rise in Biomedical and Medical Research in Japan 93
11.5.2 CHINA 95
11.5.2.1 Increasing Government and Private-sector Investments in China’s Life Sciences Market 95
11.5.3 INDIA 97
11.5.3.1 Booming Pharmaceutical Industry and Funds for Biotechnology 97
11.5.3.2 Development of Bioclusters to Boost the Production of Antibodies in India 97
11.5.4 REST OF ASIA 99
11.5.4.1 Rising Pharmaceutical and Biotechnology R&D Activities in Korea 99
11.5.4.2 Government Support for Strong Academic and Commercial R&D Activities in Taiwan 100
11.5.4.3 AbbVie’s Expansion into Singapore is Likely to Augment the Market in the Country 100
11.6 REST OF THE WORLD (ROW) 102
11.6.1 LATIN AMERICA 105
11.6.1.1 Pharmaceutical, Biotechnology, and Research Industries in Brazil to Bolster the Market 105
11.6.1.2 Mexico, the Production Hub for Global Pharmaceutical Companies 105
11.6.2 MIDDLE EAST AND AFRICA 107
11.6.2.1 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and UAE 107
11.6.2.2 Increasing Focus on Africa by Pharmaceutical Companies 108
11.6.3 PACIFIC COUNTRIES 109
11.6.3.1 Favorable Regulatory Changes to Increase the Market in New Zealand and Australia 109
11.6.3.2 Federal Collaborations in Australia 110
12 COMPETITIVE LANDSCAPE 112
12.1 OVERVIEW 112
12.2 MARKET SHARE ANALYSIS, ANTIBODY PRODUCTION MARKET 113
12.2.1 GE HEALTHCARE 114
12.2.2 THERMO FISHER SCIENTIFIC, INC. 114
12.2.3 SARTORIUS AG 115
12.3 COMPETITIVE SITUATION AND TRENDS 115
12.3.1 AGREEMENTS/PARTNERSHIPS/JOINT VENTURES/COLLABORATIONS 116
12.3.2 EXPANSIONS 117
12.3.3 NEW PRODUCT LAUNCHES 118
12.3.4 ACQUISITIONS 119
12.3.5 OTHERS 120
13 COMPANY PROFILES 121
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 INTRODUCTION 121
13.2 GE HEALTHCARE 122
13.3 THERMO FISHER SCIENTIFIC, INC. 125
13.4 SARTORIUS AG 129
13.5 MERCK MILLIPORE 132
13.6 SIGMA-ALDRICH CORPORATION 135
13.7 ABCAM PLC 139
13.8 ROCHE APPLIED SCIENCE 142
13.9 AMGEN, INC. 145
13.10 SANOFI S. A. 148
13.11 ROCKLAND IMMUNOCHEMICALS, INC. 150
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
14 APPENDIX 153
14.1 DISCUSSION GUIDE 153
14.2 COMPANY DEVELOPMENTS (2012–2014) 157
14.2.1 GE HEALTHCARE 157
14.2.2 THERMO FISHER SCIENTIFIC, INC. 157
14.2.3 SARTORIUS AG 158
14.2.4 MERCK MILLIPORE 159
14.2.5 SIGMA-ALDRICH CORPORATION 159
14.2.6 ROCHE APPLIED SCIENCE 160
14.2.7 AMGEN, INC. 161
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 162
14.4 AVAILABLE CUSTOMIZATIONS 162
14.5 RELATED REPORTS 163